Navigation Links
Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Date:6/22/2013

erience will be consistent with study findings to date or that empagliflozin* will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

CONTACT:

Catherine London
Associate Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: usnews@boehringer-ingelheim.com
Phone: (203) 798-4638

Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: (317) 651-9116

References

  1. Haring H, et al. Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients with Type 2 diabetes (T2DM). Poster No: 1092-P. Presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®. June 21-25, Chicago, IL.
  2. Haring H, et al. Empagliflozin as Add-On to Metformin Plus Sulfonylurea (SU) for 24 Weeks Improves Glycemic Control in Patients with Type 2 diabetes (T2DM). Poster No: 1082-P. Presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®. June 21-25, Chicago, IL.
  3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Center for Disease Control and Prevention, 2011.
  4. International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012.
  5. International Diabetes Feder
    '/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015 Trinity Biotech plc (Nasdaq: ... of diagnostic products for the point-of-care and clinical ... Limited, its wholly-owned subsidiary (the "Issuer"), intends to ... million aggregate principal amount of Exchangeable Senior Notes ... institutional buyers pursuant to Rule 144A under the ...
(Date:4/1/2015)... 1, 2015  Pittman Motors has significantly expanded ... PLG42K, PLG42S, PLG52, and PLG63 planetary gearboxes. These ... brushless DC motors and complement Pittman,s existing spur ... 35 standard motor-gearbox family combinations to the Pittman ... high torque loads with excellent efficiency and are ...
(Date:4/1/2015)... MOUNTAIN VIEW, Calif. , April 1, ... ) announces that it has signed a definitive ... device company that develops, manufactures and sells minimally ... drainage of targeted areas within the gastrointestinal tract. ... The Xlumena portfolio includes the ...
Breaking Medicine Technology:Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 2Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 3Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 4Pittman Motors Expands PLG Planetary Gearbox Offering 2Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
(Date:4/1/2015)... NTOCC today launches the Knowledge & ... that seek to improve care transitions and positively impact ... to bring light to tools or resources that align ... the healthcare industry through the promotion of public policy, ... Following that vision, the Knowledge & Resource Center serves ...
(Date:4/1/2015)... After a particularly harsh winter, many roads ... lead to costly damage, so Amica Insurance has ... the following suggestions from AAA: , , ... inflated to the manufacturer’s recommended levels. , ... and uneven tire wear can be signs of bad shocks ...
(Date:4/1/2015)... April 01, 2015 The Pennsylvania Court ... lawsuits ( http://www.risperdallawsuit2014.com/ ) has scheduled a meeting ... the Philadelphia Court of Common Pleas, the meeting will ... Hall. Court records indicate that the proceeding will address ... of Risperdal users who experienced gynecomastia (male breast growth) ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 EAGAN, Minn. ... Minnesota and its family of companies (Blue Cross) today ... out the year with net income of $61.5 million, ... losses. The organization reported a net operating loss of ... a negative operating margin of one-tenth of one percent ...
(Date:4/1/2015)... Parents of teenaged and adolescent children ... the latest post discusses Teen Violence Related to Substance ... Dating Violence Awareness Month, the substance abuse treatment center ... help parents identify if there may be problems with ... drugs or alcohol. , “People learn how to establish ...
Breaking Medicine News(10 mins):Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 2Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 3Health News:Prepare for potholes with 7 tips from Amica Insurance 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2
... ... Saunders for Chairman of the President,s Council on Physical Fitness & Sports ... will be held February 10 at 2:35 PM on the Senate Floor ... appointment to chairman of the President,s Council on Physical Fitness & Sports ...
... ... On WaveMaker Cloud Development Platform and Amazon EC2 , ... San Francisco, CA (PRWEB) -- WaveMaker Software™, the ... using WaveMaker and Amazon EC2. This application makes malaria research data available through a ...
... researchers say , , MONDAY, Feb. 8 (HealthDay News) ... and the antidepressant Paxil may increase their risk of ... , "Paxil can deprive women of the benefit of ... tamoxifen for a long time," said lead researcher Dr. ...
... , Feb. 8 Since 2003, Amway has mobilized ... better lives for children in need. , Now in its ... Children has improved the lives of an estimated 7 million children ... global impact. , Employees and distributors alike have volunteered more ...
... Ewing sarcoma: potential new drug target? Ewing ... that affects children and young adults. The protein CD99 is ... in the disease is unknown. Now, Katia Scotlandi and colleagues, ... have identified a crucial role for CD99 in the development ...
... occurs in the corneas of mountain climbers, but does ... to 6,300 meters (about 20,670 feet), according to a ... Ophthalmology, one of the JAMA/Archives journals. "High-altitude ... the authors write as background information in the article. ...
Cached Medicine News:Health News:Senator Janis Lee Sponsors Senate Resolution Supporting Kevin Saunders for Chairman of the President's Council on Physical Fitness & Sports 2Health News:Senator Janis Lee Sponsors Senate Resolution Supporting Kevin Saunders for Chairman of the President's Council on Physical Fitness & Sports 3Health News:Senator Janis Lee Sponsors Senate Resolution Supporting Kevin Saunders for Chairman of the President's Council on Physical Fitness & Sports 4Health News:MARA Fights Malaria With WaveMaker and Amazon Web Services 2Health News:MARA Fights Malaria With WaveMaker and Amazon Web Services 3Health News:MARA Fights Malaria With WaveMaker and Amazon Web Services 4Health News:Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer 2Health News:Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer 3Health News:Amway One by One Campaign for Children Reaches 7 Million Kids 2Health News:Amway One by One Campaign for Children Reaches 7 Million Kids 3Health News:JCI online early table of contents: Feb. 8, 2010 2Health News:JCI online early table of contents: Feb. 8, 2010 3Health News:JCI online early table of contents: Feb. 8, 2010 4Health News:JCI online early table of contents: Feb. 8, 2010 5Health News:JCI online early table of contents: Feb. 8, 2010 6Health News:High-altitude climbs may cause corneal swelling, but do not appear to affect vision 2
... monitors and controls patient temperature primarily in ... surgery, trauma, or other medical conditions. The ... provided from a patient temperature probe. Circulating ... and 42C (107.6F) to achieve a preset ...
... The Littmann Electronic Stethoscope Model 4100WS ... (ANR) technology allowing you to reduce ambient ... without eliminating critical body sounds. Three frequency ... lung, and other body sounds: Bell (20-200 ...
... The OmniMD orthopedics EMR addresses the vast ... specific EMR includes clinically-defined templates for common ... review of systems. The system also includes ... are used to capture accurate charges and ...
Intrinsic Dual Chamber ICD With MVP Mode (Managed Ventricular Pacing). MVP promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular (RV) pacing to approximately...
Medicine Products: